腹膜透析患者感染性腹膜炎治疗中抗生素给药途径的探讨_West China Medical Journal

Authors：

 王晨 ,  费小凡 , 饶凡 , 苏兰 , 徐萍蓉

四川大学华西医院药剂科（成都 610041）;

Corresponding author：

王晨, Email: 505484571@qq.com; 费小凡, Email: fxiaofan@yahoo.com.cn

Keywords：

腹膜透析; 感染性腹膜炎; 抗生素; 给药途径

DOI：

10.7507/1002-0179.20150513

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

腹膜透析是肾病患者到尿毒症或肾脏衰竭期所采用的一种有效的治疗方法，但患者常常由于反复的并发症不得不提早终止腹膜透析，甚至危及生命。感染性腹膜炎是腹膜透析治疗中最常见的并发症，目前国内外较多采用腹腔给药的方式治疗腹膜透析患者的感染性腹膜炎，但这种给药途径在对腹膜的刺激、对肝肾的损伤、药物稳定性、药物相互作用方面均存在多种风险。建议临床使用抗生素治疗腹膜透析患者的感染性腹膜炎时，考虑多方面的因素及风险，选择最适合的给药途径。现结合目前国内外的治疗方法及抗生素使用情况，探讨腹膜透析患者感染性腹膜炎治疗中抗生素的给药途径。

Citation： 王晨, 费小凡, 饶凡, 苏兰, 徐萍蓉. 腹膜透析患者感染性腹膜炎治疗中抗生素给药途径的探讨. West China Medical Journal, 2015, 30(9): 1793-1797. doi: 10.7507/1002-0179.20150513 Copy

1.	Abstracts:the American Society of Nephrology. Chicago, Illinois, December 12-14, 1982[J]. Kidney Int, 1983, 23(1):93-298.
2.	Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis:a systematic review of randomized controlled trials[J]. Am J Kidney Dis, 2004, 44(4):591-603.
3.	Peritoneal Dialysis Adequacy Work Group. Clinical practice guidelines for peritoneal dialysis adequacy[J]. Am J Kidney Dis, 2006, 48(Suppl 1):S98-S129.
4.	Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations:2005 update[J]. Perit Dial Int, 2005, 25(2):107-131.
5.	Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Evidence for peritonitis treatment and prophylaxis:prophylactic antibiotics for insertion of peritoneal dialysis catheter[J]. Nephrology (Carlton), 2004, 9(Suppl 3):S72-S75.
6.	Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis:a systematic review of randomized, controlled trials[J]. J Am Soc Nephrol, 2004, 15(10):2735-2746.
7.	黎伟, 廖蕴华, 薛超, 等. 腹膜透析相关性腹膜炎相关因素分析[J]. 广东医学, 2007, 28(8):1292-1294.
8.	Barbosa D, Lima L, Silbert S, et al. Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant Enterococcus among patients on dialysis[J]. Am J Kidney Dis, 2004, 44(2):337-343.
9.	O'Riordan A, Abraham KA, Ho JK, et al. Vancomycin-resistant Peritonitis associated with peritoneal dialysis:a cause for concern[J]. Ir J Med Sci, 2002, 171(1):42-43.
10.	Passadakis P, Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis[J]. Adv Perit Dial, 2001, 17:180-190.
11.	Morse GD, Farolino DF, Apicella MA, et al. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis[J]. Antimicrob Agents Chemother, 1987, 31(2):173-177.
12.	Tosukhowong T, Eiam-Ong S, Thamutok K, et al. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 2002, 21(6):587-594.
13.	Bouza P, García Falcón T, Pérez Fontán M, et al. Treatment of CAPD-related peritonitis with ciprofloxacin:results after seven years[J]. Adv Perit Dial, 1996, 12:185-188.
14.	Pérez Fontán M, Rosales M, Rodríguez-Carmona A, et al. Treatment of peritonitis in CAPD with ciprofloxacin:long-term experience[J]. Adv Perit Dial, 1993, 9:211-214.
15.	Van Biesen W, Vanholder R, Vogelaers D, et al. The need for a center-tailored treatment protocol for peritonitis[J]. Perit Dial Int, 1998, 18(3):274-281.
16.	Nye KJ, Gibson SP, Nwosu AC, et al. Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients:preliminary report[J]. Perit Dial Int, 1993, 13(1):59-60.
17.	Celik A, Cirit M, Tünger A, et al. Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination[J]. Perit Dial Int, 1999, 19(3):284-285.
18.	Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis:review of 245 consecutive cases[J]. Clin J Am Soc Nephrol, 2007, 2(2):245-251.
19.	郭群英, 陈林, 阳晓, 等. 腹膜透析相关感染性腹膜炎致病菌及菌谱变化——单个腹膜透析中心15年回顾分析[J]. 中华肾脏病杂志, 2006, 22(12):719-724.
20.	Krishnan M, Thodis E, Ikonomopoulos D, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis[J]. Perit Dial Int, 2002, 22(5):573-581.
21.	吕鹏. 腹膜透析相关腹膜炎致病菌及耐药性分析(附65例报告)[J]. 中国现代药物应用, 2012, 1(6):82-83.
22.	吴晶晶, 刘佳, 张莉, 等. 腹膜透析相关性腹膜炎致病菌及耐药性分析[J]. 中华医院感染学杂志, 2011, 16(16):3521-3523.
23.	贺全仁, 陈孝治. 耐甲氧西林金葡球菌的药物防治[J]. 国外医药:抗生素分册, 1997, 18(6):442-443, 472.
24.	Krothapalli RK, Senekjian HO, Ayus JC. Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis[J]. Am J Med, 1983, 75(2):345-348.
25.	程莉, 候凡凡, 张训, 等. CAPD相关性腹膜硬化[J]. 国外医学:泌尿系统分册, 1996, 16(2):67-70.
26.	Barratt M, Davison AMA, Cameron JS, et al. Oxford textbook of clinical nephrology[M]. Oxford:Oxford University Press, 1992:1477-1505.
27.	Taipale J, Saharinen J, Hedman K, et al. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils[J]. J Histochem Cytochem, 1996, 44(8):875-889.
28.	田文谋, 于德昌. 腹膜炎[M]. 北京:人民卫生出版社, 1988:8.
29.	Shemin D, Maaz D, St Pierre D, et al. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients[J]. Am J Kidney Dis, 1999, 34(1):14-20.
30.	白建伟, 晋援朝, 白林, 等. 氟康唑与四种抗生素的配伍和稳定性[J]. 第四军医大学学报, 2004, 25(12):1140-1142.
31.	牛凤珍, 毕秀云. 可夫新与头孢哌酮钠舒巴坦钠存在配伍禁忌[J]. 临床护理杂志, 2009, 3(3):69.
32.	李健, 周燕文, 马妮飞. 氟罗沙星注射液与4种抗生素配伍的稳定性[J]. 中国医院药学杂志, 2002, 1(1):61-62.
33.	毛文, 周少怀, 柯国平. 加替沙星注射液与4种抗生素配伍的稳定性[J]. 数理医药学杂志, 2007, 4(4):530-531.
34.	陈灏珠. 实用内科学[M]. 11版. 北京:人民卫生出版社, 2002:1789-1791.
35.	郑芝田. 胃肠病学[M]. 3版. 北京:人民卫生出版社, 2000:839-843.

1. Abstracts:the American Society of Nephrology. Chicago, Illinois, December 12-14, 1982[J]. Kidney Int, 1983, 23(1):93-298.
2. Strippoli GF, Tong A, Johnson D, et al. Antimicrobial agents to prevent peritonitis in peritoneal dialysis:a systematic review of randomized controlled trials[J]. Am J Kidney Dis, 2004, 44(4):591-603.
3. Peritoneal Dialysis Adequacy Work Group. Clinical practice guidelines for peritoneal dialysis adequacy[J]. Am J Kidney Dis, 2006, 48(Suppl 1):S98-S129.
4. Piraino B, Bailie GR, Bernardini J, et al. Peritoneal dialysis-related infections recommendations:2005 update[J]. Perit Dial Int, 2005, 25(2):107-131.
5. Caring for Australians with Renal Impairment (CARI). The CARI guidelines. Evidence for peritonitis treatment and prophylaxis:prophylactic antibiotics for insertion of peritoneal dialysis catheter[J]. Nephrology (Carlton), 2004, 9(Suppl 3):S72-S75.
6. Strippoli GF, Tong A, Johnson D, et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis:a systematic review of randomized, controlled trials[J]. J Am Soc Nephrol, 2004, 15(10):2735-2746.
7. 黎伟, 廖蕴华, 薛超, 等. 腹膜透析相关性腹膜炎相关因素分析[J]. 广东医学, 2007, 28(8):1292-1294.
8. Barbosa D, Lima L, Silbert S, et al. Evaluation of the prevalence and risk factors for colonization by vancomycin-resistant Enterococcus among patients on dialysis[J]. Am J Kidney Dis, 2004, 44(2):337-343.
9. O'Riordan A, Abraham KA, Ho JK, et al. Vancomycin-resistant Peritonitis associated with peritoneal dialysis:a cause for concern[J]. Ir J Med Sci, 2002, 171(1):42-43.
10. Passadakis P, Oreopoulos D. The case for oral treatment of peritonitis in continuous ambulatory peritoneal dialysis[J]. Adv Perit Dial, 2001, 17:180-190.
11. Morse GD, Farolino DF, Apicella MA, et al. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis[J]. Antimicrob Agents Chemother, 1987, 31(2):173-177.
12. Tosukhowong T, Eiam-Ong S, Thamutok K, et al. Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 2002, 21(6):587-594.
13. Bouza P, García Falcón T, Pérez Fontán M, et al. Treatment of CAPD-related peritonitis with ciprofloxacin:results after seven years[J]. Adv Perit Dial, 1996, 12:185-188.
14. Pérez Fontán M, Rosales M, Rodríguez-Carmona A, et al. Treatment of peritonitis in CAPD with ciprofloxacin:long-term experience[J]. Adv Perit Dial, 1993, 9:211-214.
15. Van Biesen W, Vanholder R, Vogelaers D, et al. The need for a center-tailored treatment protocol for peritonitis[J]. Perit Dial Int, 1998, 18(3):274-281.
16. Nye KJ, Gibson SP, Nwosu AC, et al. Single-dose intraperitoneal vancomycin and oral ciprofloxacin for the treatment of peritonitis in CAPD patients:preliminary report[J]. Perit Dial Int, 1993, 13(1):59-60.
17. Celik A, Cirit M, Tünger A, et al. Treatment of CAPD peritonitis with oral trimethoprim/sulfamethoxazole and intraperitoneal aminoglycoside combination[J]. Perit Dial Int, 1999, 19(3):284-285.
18. Szeto CC, Chow KM, Kwan BC, et al. Staphylococcus aureus peritonitis complicates peritoneal dialysis:review of 245 consecutive cases[J]. Clin J Am Soc Nephrol, 2007, 2(2):245-251.
19. 郭群英, 陈林, 阳晓, 等. 腹膜透析相关感染性腹膜炎致病菌及菌谱变化——单个腹膜透析中心15年回顾分析[J]. 中华肾脏病杂志, 2006, 22(12):719-724.
20. Krishnan M, Thodis E, Ikonomopoulos D, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis[J]. Perit Dial Int, 2002, 22(5):573-581.
21. 吕鹏. 腹膜透析相关腹膜炎致病菌及耐药性分析(附65例报告)[J]. 中国现代药物应用, 2012, 1(6):82-83.
22. 吴晶晶, 刘佳, 张莉, 等. 腹膜透析相关性腹膜炎致病菌及耐药性分析[J]. 中华医院感染学杂志, 2011, 16(16):3521-3523.
23. 贺全仁, 陈孝治. 耐甲氧西林金葡球菌的药物防治[J]. 国外医药:抗生素分册, 1997, 18(6):442-443, 472.
24. Krothapalli RK, Senekjian HO, Ayus JC. Efficacy of intravenous vancomycin in the treatment of gram-positive peritonitis in long-term peritoneal dialysis[J]. Am J Med, 1983, 75(2):345-348.
25. 程莉, 候凡凡, 张训, 等. CAPD相关性腹膜硬化[J]. 国外医学:泌尿系统分册, 1996, 16(2):67-70.
26. Barratt M, Davison AMA, Cameron JS, et al. Oxford textbook of clinical nephrology[M]. Oxford:Oxford University Press, 1992:1477-1505.
27. Taipale J, Saharinen J, Hedman K, et al. Latent transforming growth factor-beta 1 and its binding protein are components of extracellular matrix microfibrils[J]. J Histochem Cytochem, 1996, 44(8):875-889.
28. 田文谋, 于德昌. 腹膜炎[M]. 北京:人民卫生出版社, 1988:8.
29. Shemin D, Maaz D, St Pierre D, et al. Effect of aminoglycoside use on residual renal function in peritoneal dialysis patients[J]. Am J Kidney Dis, 1999, 34(1):14-20.
30. 白建伟, 晋援朝, 白林, 等. 氟康唑与四种抗生素的配伍和稳定性[J]. 第四军医大学学报, 2004, 25(12):1140-1142.
31. 牛凤珍, 毕秀云. 可夫新与头孢哌酮钠舒巴坦钠存在配伍禁忌[J]. 临床护理杂志, 2009, 3(3):69.
32. 李健, 周燕文, 马妮飞. 氟罗沙星注射液与4种抗生素配伍的稳定性[J]. 中国医院药学杂志, 2002, 1(1):61-62.
33. 毛文, 周少怀, 柯国平. 加替沙星注射液与4种抗生素配伍的稳定性[J]. 数理医药学杂志, 2007, 4(4):530-531.
34. 陈灏珠. 实用内科学[M]. 11版. 北京:人民卫生出版社, 2002:1789-1791.
35. 郑芝田. 胃肠病学[M]. 3版. 北京:人民卫生出版社, 2000:839-843.

Previous Article
哺乳动物雷帕霉素靶蛋白信号通路与淋巴瘤的治疗研究进展
Next Article
急性胸痛带状疱疹误诊为心肌梗死一例

West China Medical Journal

腹膜透析患者感染性腹膜炎治疗中抗生素给药途径的探讨

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content